JANX - NASDAQ
Janux Therapeutics, Inc.
$13.59
-1.4%Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
At a Glance
Live SnapshotJanux Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Janux Therapeutics, Inc. Income Statement
JANX • NASDAQ
| Janux Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
10M | 10.6M | 8.1M | 8.6M | 3.6M | 0.0 | 0.0 | |
GROSS PROFIT | |||||||
(2M) | (2.1M) | (2M) | (841K) | (0.0) | (13K) | (6K) | |
8M | 8.5M | 6.1M | 7.8M | 3.6M | -13K | -6K | |
OPERATING INCOME | |||||||
(165.6M) | (107.4M) | (79.1M) | (74.9M) | (36.6M) | (4.8M) | (3.8M) | |
(41.8M) | (41M) | (26.1M) | (22.3M) | (10.3M) | (1.8M) | (772K) | |
(125.9M) | (68.4M) | (54.9M) | (53.4M) | (26.2M) | (3M) | (3M) | |
-157.7M | -98.8M | -73M | -67.1M | -32.9M | -4.8M | -3.8M | |
PRE-TAX INCOME | |||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (206K) | (233K) | |
44M | 29.9M | 14.7M | 4M | 257K | 0.0 | 0.0 | |
-2M | -2.1M | -2M | -841K | (0.0) | (0.0) | (0.0) | |
44M | 29.9M | 14.7M | 4M | 257K | -1.9M | -233K | |
-113.6M | -69M | -58.3M | -63.1M | -32.7M | -6.8M | -4M | |
NET INCOME | |||||||
-113.6M | -69M | -58.3M | -63.1M | -32.7M | -6.8M | -4.2M |
SEC Filings
JANX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 22, 2026 | January 21, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 19, 2025 | September 18, 2025 | 2025 |
Related Guides
Continue your JANX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.